Brief: Sangamo Therapeutics Announces Alignment With FDA On Accelerated Approval Pathway For St-920 In Fabry Disease With BLA Submission Expected In 2025
22/10/2024 13:54
Oct 22 (Reuters) - Sangamo Therapeutics Inc SGMO.O :
* SANGAMO THERAPEUTICS ANNOUNCES ALIGNMENT WITH FDA ON
ACCELERATED
APPROVAL PATHWAY FOR ST-920 IN FABRY DISEASE WITH BLA SUBMISSION
EXPECTED IN 2025
* SANGAMO THERAPEUTICS INC - FDA CONFIRMS EGFR SLOPE DATA
CAN
SERVE AS BASIS FOR APPROVAL
* SANGAMO THERAPEUTICS: POTENTIAL BIOLOGICS LICENSE
APPLICATION
SUBMISSION EXPECTED IN H2 OF 2025
Source text for Eikon: ID:nBw936n1Ra
Further company coverage: SGMO.O
((Reuters.Briefs@thomsonreuters.com))